Clinical Trials for Pancreas Cancer

Phase 1 Dose Escalation Study of Systemically Administered IL13Ra2 Chimeric Antigen Receptor (CAR) T Cells After a Nonmyeloablative Conditioning Regimen in Patients With Metastatic Melanoma and Other Solid Tumors

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with metastatic melanoma (including prior brain metastases) or other relapsed/refractory, IL13Ralpha2-expressing solid tumors to receive lymphodepleting chemotherapy followed by systemic infusion of autologous CAR T cells targeting IL13Ralpha2, a tumor-associated antigen. Patients must have good performance status and tumors confirmed to express IL13Ralpha2 by immunohistochemistry.

ClinicalTrials.gov ID: NCT04119024

A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to Patients With CD70-Expressing Cancers

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with metastatic or unresectable CD70-expressing cancers (including clear cell renal cell carcinoma and other solid tumors) who have progressed after at least one prior therapy, to receive a lymphodepleting regimen followed by infusion of autologous T cells genetically engineered with an anti-CD70 chimeric antigen receptor targeting CD70-positive tumor cells, plus high-dose aldesleukin (IL-2) post-infusion.

ClinicalTrials.gov ID: NCT02830724

A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of TROP2-Directed Antibody-Drug Conjugate LCB84, as a Single Agent and in Combination With an Anti-PD-1 Ab, in Patients With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable advanced solid tumors refractory to standard therapy or lacking a standard option, and ECOG performance status 0–1, receive IV LCB84 alone or with an anti-PD-1 antibody; expansion cohorts focus on selected tumor types. LCB84 is a TROP2-directed antibody–drug conjugate that delivers the cytotoxic payload monomethyl auristatin E.

ClinicalTrials.gov ID: NCT05941507

A Phase I, Open-label, Non-randomised, Multi-center Dose Escalation Trial of BI 765049 Administered by Parenteral Route in Patients With Advanced, Unresectable, and/or Metastatic Colorectal Carcinoma (CRC), Gastric Carcinoma (GC), or Pancreatic Ductal Adenocarcinoma (PDAC) to Determine the MTD and the RP2D and to Determine the Dosing Regimen for Further Development of BI 765049

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced, unresectable or metastatic colorectal, gastric, or pancreatic ductal adenocarcinoma after prior treatment failure or with no available treatment receive parenteral BI 765049 on one of two dosing regimens; European enrollment is limited to colorectal cancer. BI 765049 is a bispecific antibody that binds B7-H6 on tumor cells and CD3 on T cells to promote tumor-cell killing.

ClinicalTrials.gov ID: NCT06882746

A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Eligible patients are adults with metastatic or unresectable solid tumors harboring a G12V mutation in KRAS, NRAS, or HRAS who are HLA-A*11:01 positive and have progressed on or declined standard therapies. Treatment involves lymphodepleting chemotherapy followed by infusion of autologous peripheral blood lymphocytes genetically modified to express a murine T-cell receptor targeting the G12V RAS mutation, along with high-dose aldesleukin.

ClinicalTrials.gov ID: NCT03190941

A Phase 1, First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC028 in Participants With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable, unresectable locally advanced or metastatic NSCLC adenocarcinoma, cholangiocarcinoma, colorectal cancer, or pancreatic cancer after standard therapy or without a suitable standard option receive intravenous MGC028. This investigational ADAM9-targeted antibody–drug conjugate delivers exatecan, a topoisomerase I inhibitor.

ClinicalTrials.gov ID: NCT06723236

A Phase I/IIa Image-Guided, Alpha-Particle Therapy Study of [203Pb]Pb-PSV359 and [212Pb]Pb-PSV359 in Patients With Solid Tumors That Are Known to be Fibroblast Activation Protein (FAP)-Positive

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with locally advanced or metastatic solid tumors that have progressed after standard therapy or lack a standard option are eligible if at least one lesion shows uptake on [203Pb]Pb-PSV359 SPECT/CT. The imaging agent selects patients for treatment with [212Pb]Pb-PSV359, a FAP-targeted peptide that delivers alpha-particle radiation.

ClinicalTrials.gov ID: NCT06710756

An Open-label, Multicenter, Phase 1/2a Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumour Activity of WEF-001 in Participants With Advanced KRAS- Mutant Solid Tumours.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Patients with measurable, progressive KRAS-mutant pancreatic, colorectal, lung, platinum-resistant serous ovarian, cholangiocarcinoma, or urothelial bladder cancer after at least one standard therapy receive intravenous WEF-001 monotherapy. WEF-001 is investigational and is proposed to exploit macropinocytosis in KRAS-mutant tumors; direct KRAS inhibition has not been established.

ClinicalTrials.gov ID: NCT07148128

A Phase 1 Study of ASP5834 in Participants With Locally Advanced (Unresectable) or Metastatic Solid Tumor Malignancies With KRAS Mutations or KRAS Amplifications

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable locally advanced or metastatic solid tumors harboring specified KRAS mutations or eligible KRAS amplification receive intravenous ASP5834, an investigational agent designed to degrade mutant or amplified KRAS. Patients with KRAS-mutated colorectal adenocarcinoma may receive ASP5834 with panitumumab, an anti-EGFR antibody.

ClinicalTrials.gov ID: NCT07094204

A Phase 1/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable, locally advanced or metastatic KRAS-mutant or KRAS-amplified solid tumors who have no remaining standard treatment options or have declined them receive oral AMG 410, a reversible pan-KRAS inhibitor, alone or with the PD-1 inhibitor pembrolizumab. Patients with colorectal or pancreatic cancer may receive AMG 410 with the EGFR-targeting antibody panitumumab.

ClinicalTrials.gov ID: NCT07094113